Haploidentical Hematopoietic Transplantation Without T-cell Depletion: Current Status and Future Perspectives

Overview

Journal Stem Cell Investig

Publisher AME Publishing Company

Date 2016 Jul 1

PMID 27358888

Citations 1

Authors

Lei Gao

Xi Zhang

Affiliations

Soon will be listed here.

Abstract

Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) without T-cell depletion has tremendously progressed over the past 20 years and has become a feasible treatment option for leukemia patients without an HLA-identical sibling donor. Advances in conditioning regimens, graft manipulation, and pharmacological graft-versus-host disease (GVHD) prophylaxis have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. According to clinical observations, killer immunoglobulin-like receptor (KIR) mismatch and donor-specific anti-HLA (DSA) antibodies-negative status play potential roles in reducing the risk of GVHD and graft failure following HLA-haploidentical SCT. New strategies to improve transplant outcomes include donor lymphocyte, NK cell and selected T-cell subset infusion, mesenchymal stem cell (MSC) co-transplantation and interleukin-2 (IL-2) application. Future challenges remain in improving post-transplant immune reconstitution and finding the best approach to reduce the incidence and severity of GVHD while simultaneously preserving the graft-versus leukemia effect to prevent the recurrence of underlying malignancy.

Citing Articles

ABO Blood Type Incompatibility Is Not a Risk Factor of Outcomes for Acute Myeloid Leukemia (AML) Patients After Unmanipulated Haplo-identical Peripheral Blood Hematopoietic Stem Cell Transplantation.

Yang N, Guan L, Liu Z, Ding Y, Zhu C, Luo L Ann Transplant. 2019; 24:350-358.

PMID: 31197126 PMC: 6589049. DOI: 10.12659/AOT.916004.

References

Schuster F, Meisel R, Fuhrer M, Reuther S, Hauer J, Tischer J . Anti-leukaemic activity of a novel haploidentical-transplantation approach employing unmanipulated bone marrow followed by CD6-depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia. Br J Haematol. 2013; 162(6):802-7. DOI: 10.1111/bjh.12455. View

Yoon S, Lee Y, Yang S, Ahn K, Lee J, Lee J . Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2009; 45(6):1038-46. DOI: 10.1038/bmt.2009.304. View

Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006; 38(4):291-7. DOI: 10.1038/sj.bmt.1705445. View

Zhao X, Wang X, Zhao X, Chang Y, Xu L, Zhang X . Non-traditional CD4+CD25-CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. J Transl Med. 2014; 12:187. PMC: 4089938. DOI: 10.1186/1479-5876-12-187. View

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002; 30(1):42-8. DOI: 10.1016/s0301-472x(01)00769-x. View

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Wang Y, Liu Q, Xu L, Liu K, Zhang X, Ma X . Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015; 125(25):3956-62. DOI: 10.1182/blood-2015-02-627786. View

Ball L, Bernardo M, Locatelli F, Egeler R . Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow Transplant. 2008; 42 Suppl 2:S60-6. DOI: 10.1038/bmt.2008.286. View

Ge X, Brown J, Sykes M, Boussiotis V . CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant. 2008; 14(5):518-30. PMC: 2423190. DOI: 10.1016/j.bbmt.2008.02.010. View

10.

Liu K, Chen Y, Liu D, Xu L, Huang X . A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2008; 42(8):535-9. DOI: 10.1038/bmt.2008.208. View

11.

Zhang X, Li Y, Zhang Y, Chen X, Zhang C, Gao L . Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China. Leuk Res. 2013; 37(6):657-64. DOI: 10.1016/j.leukres.2013.03.005. View

12.

Wang Z, Shi B, Jin H, Xiao L, Chen Y, Qian Y . Low-dose of tacrolimus favors the induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation. Int Immunopharmacol. 2009; 9(5):564-9. DOI: 10.1016/j.intimp.2009.01.029. View

13.

Aggarwal S, Pittenger M . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004; 105(4):1815-22. DOI: 10.1182/blood-2004-04-1559. View

14.

Jacobson P, Uberti J, Davis W, Ratanatharathorn V . Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998; 22(3):217-25. DOI: 10.1038/sj.bmt.1701331. View

15.

Reisner Y, Hagin D, Martelli M . Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011; 118(23):6006-17. DOI: 10.1182/blood-2011-07-338822. View

16.

Kendal A, Chen Y, Regateiro F, Ma J, Adams E, Cobbold S . Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med. 2011; 208(10):2043-53. PMC: 3182049. DOI: 10.1084/jem.20110767. View

17.

Symons H, Leffell M, Rossiter N, Zahurak M, Jones R, Fuchs E . Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 16(4):533-42. PMC: 2848533. DOI: 10.1016/j.bbmt.2009.11.022. View

18.

Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D . Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002; 99(4):1159-64. DOI: 10.1182/blood.v99.4.1159. View

19.

Lai Y, Chen Y, Hu D, Jiang M, Liu Q, Liu L . Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014; 7:59. PMC: 4237802. DOI: 10.1186/s13045-014-0059-3. View

20.

Solano C, Benet I, Remigia M, de la Camara R, Munoz-Cobo B, Costa E . Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation. 2011; 92(4):e17-20. DOI: 10.1097/TP.0b013e318224f263. View